FP-014:Prostate Cancer

FP-014 (Triptorelin) is a ready-to-use, subcutaneous, long-acting injectable dosage form, administered either every three months or six months, thereby reducing the frequency of administration to patients to ensure better compliance.

Triptorelin is a common palliative treatment for men with advanced or metastatic prostate cancer. It is also prescribed for the treatment of breast cancer, precocious puberty, endometriosis or uterine fibroids, etc.

FP-014 ready-to-use, subcutaneous, 3 and 6 month LAI development candidates were selected and all necessary CMC, IND-enabling and clinical activities have been initiated in order to start P3 registration studies in 2025.